Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations.
Maria KaparouZbigniew RudzkiHannah GilesVidhya MurthySwathy SrinathRebecca LloydMaria Zahid AhmedBeena SalhanSaleena ChauhanBhuvan KishoreRichard LovellClaire HorganShankara PaneeshaEvgenia XenouAnand LokareJoanne EwingHansini DassanayakeEmmanouil NikolousisAlexandros KanellopoulosPublished in: Case reports in hematology (2021)
The present study describes a patient aged 70 with very high-risk AML who successfully received a nonmyeloablative matched unrelated donor allograft shortly following SARS-CoV-2 infection, which manifested with mild cough, interstitial abnormalities on chest CT, and pancytopenia with profound bone marrow biopsy histological alterations. In parallel, our study provides bone marrow biopsy data in a series of contemporary patients with serious haematological diseases who had a bone marrow biopsy performed within two weeks of PCR confirmation of SARS-CoV-2 infection. This study is notable because there are no published data describing the bone marrow biopsy changes observed in patients with haematological malignancies and SARS-CoV-2 infection. Finally, it is suggested that nonmyeloablative hematopoietic stem cell transplantation for very high-risk haematological malignancies can be successfully performed following recovery from SARS-CoV-2 infection.
Keyphrases
- bone marrow
- stem cell transplantation
- mesenchymal stem cells
- sars cov
- ultrasound guided
- respiratory syndrome coronavirus
- acute myeloid leukemia
- fine needle aspiration
- high dose
- computed tomography
- electronic health record
- coronavirus disease
- magnetic resonance
- big data
- deep learning
- allogeneic hematopoietic stem cell transplantation
- artificial intelligence
- contrast enhanced
- positron emission tomography
- cord blood
- meta analyses